Elotuzumab for multiple myelomaJanuary 14, 2019
Bristol-Myers Squibb and AbbVie said US FDA approved elotuzumab (Empliciti) for the treatment of multiple myeloma as a combination therapy with lenalidomide and dexamethasone (ERd) in patients who have received one to three prior therapies.
Elotuzumab is an immunostimulatory antibody that specifically targets Signaling Lymphocyte Activation Molecule Family member 7 (SLAMF7), a cell-surface glycoprotein. SLAMF7 is expressed on myeloma cells independent of cytogenetic abnormalities. SLAMF7 is also expressed on natural killer cells, plasma cells, and at lower levels on specific immune cell subsets of differentiated cells within the hematopoietic lineage.
The drug has a dual mechanism-of-action. It directly activates the immune system through natural killer cells via the SLAMF7 pathway. Elotuzumab also targets SLAMF7 on myeloma cells, tagging these malignant cells for natural killer cell-mediated destruction via antibody-dependent cellular toxicity.
The approval for multiple myeloma is based on data from the randomized, open-label, Phase 3, ELOQUENT-2 study, which demonstrated that the ERd regimen resulted in a 30% reduction in the risk of disease progression or death compared to Rd alone.
Elotuzumab is available for injection for intravenous use in 300 mg and 400 mg vials.